Centric Wealth Management Has $7.89 Million Position in Eli Lilly and Company (NYSE:LLY)

Centric Wealth Management increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,537 shares of the company’s stock after acquiring an additional 156 shares during the period. Eli Lilly and Company comprises about 2.5% of Centric Wealth Management’s portfolio, making the stock its 7th biggest position. Centric Wealth Management’s holdings in Eli Lilly and Company were worth $7,891,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC raised its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Sapient Capital LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $682,139,000. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $435,736,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after buying an additional 645,473 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LLY. Truist Financial boosted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Bank of America upped their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $1.54 during trading hours on Wednesday, reaching $776.23. 1,252,671 shares of the company were exchanged, compared to its average volume of 3,067,264. The stock has a market capitalization of $737.73 billion, a P/E ratio of 114.24, a P/E/G ratio of 1.45 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The business’s 50 day simple moving average is $761.22 and its 200-day simple moving average is $674.88.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the firm posted $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.